Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Daily summary: A week closed with declines – is the market starting to fear inflation?
US OPEN: Wall Street Bleeds After Trump's Beijing Visit
Market Wrap: Stocks and metals dip as Trump-Xi summit fails to break Iran deadlock 📉 (15.05.2026)
Daily Summary: Market euphoria shows no signs of letting up 🚀